 |
|
Thyroid Suppressibility and Long-Acting Thyroid Stimulator in Thyrotoxicosis
Gerald E. Silverstein, MD;
Gerald Burke, MD, CM
Arch Intern Med. 1970;126(4):615-620.
Abstract
| |
We examined the relationship of thyroid suppressibility to long-acting thyroid stimulator (LATS) levels in 14 thyrotoxic patients on long-term treatment with antithyroid drugs (mean duration of treatment, 11.9 months). Twenty-minute131 I thyroid uptake and LATS levels before and after liothyronine sodium administration were measured before and at one- to three-month intervals during antithyroid drug treatment. Eight patients developed thyroid suppressibility during therapy; of these, three had detectable LATS levels prior to treatment and there was no decline in LATS levels with treatment and restoration of suppressibility. Of six patients whose thyroid uptake remained nonsuppressible during long-term treatment (mean, 11.1 months), LATS was undetectable in both the serum and concentrated immunoglobulin G (IgG) fraction of four. These studies suggest that in exophthalmic goiter (Graves' disease), thyroid nonsuppressibility may reflect an intrinsic thyroid abnormality rather than the presence of circulating LATS.
Author Affiliations
Chicago
From the Radioisotope Laboratory, Department of Medicine, Michael Reese Hospital and Medical Center, and the Department of Medi-; cine, University of Chicago Pritzer School of Medicine, Chicago.
Footnotes
Received for publication Jan 23, 1970; accepted June 10.
Reprint requests to Radioisotope Laboratory, Michael Reese Hospital, Chicago 60616 (Dr. Burke).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pretibial Myxedema and Nonthyrotoxic Thyroid Disease
Lynch et al.
Arch Dermatol 1973;107:107-111.
ABSTRACT
|
